UMB Bank n.a. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

UMB Bank n.a. trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 44.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 211,513 shares of the biopharmaceutical company's stock after selling 168,890 shares during the quarter. UMB Bank n.a.'s holdings in Pfizer were worth $5,611,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the 4th quarter valued at approximately $26,000. Gladius Capital Management LP increased its holdings in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP bought a new position in shares of Pfizer in the 2nd quarter valued at $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Pfizer during the 3rd quarter valued at $35,000. Finally, Joseph Group Capital Management grew its position in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 771 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. Bank of America reiterated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Finally, Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $32.00.

Pfizer Stock Up 0.8 %

Shares of PFE traded up $0.22 during trading hours on Tuesday, hitting $26.52. The stock had a trading volume of 16,560,130 shares, compared to its average volume of 32,065,213. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm has a market capitalization of $150.26 billion, a P/E ratio of 35.83, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The firm has a 50 day simple moving average of $26.08 and a 200-day simple moving average of $27.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company's quarterly revenue was up 31.2% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This is a boost from Pfizer's previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.49%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio (DPR) is currently 227.03%.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.